AMN Healthcare Presents at Goldman Sachs, Reaffirms Turnaround Narrative

What happened

AMN Healthcare presented at the Goldman Sachs Global Healthcare Conference, reiterating its strategy to stabilize nurse and allied staffing volumes and grow higher-margin technology solutions. The company emphasized that travel nurse orders are recovering, bill rates are flat, and it expects low-single-digit growth in Nurse & Allied in 2026. Management also highlighted the recent refinancing that extended maturities to 2030-31 and reduced revolver usage to zero. However, the presentation lacked new quantitative guidance, and the uplift remains heavily dependent on strike-related revenue and international nurse ramp-up. The market remains skeptical, pricing in no recovery before 2027, but the company's tone suggests cautious optimism that a cyclical trough is being reached.

Implication

AMN's Goldman Sachs presentation essentially repackaged the same themes from its Q3 2025 earnings call: nurse volumes are bottoming, bill rates have stabilized, and the company sees a path to low-single-digit growth in 2026. While the refinancing and zero revolver usage are positive liquidity signals, the core business still faces headwinds from hospital internal staffing and pricing pressure. The lack of new fiscal 2026 guidance or updated margin targets leaves investors without a fresh catalyst. The thesis that EBITDA can recover 30-50% from trough levels remains plausible but unproven, particularly if strike revenue fades and VMS recovery disappoints. Investors should demand confirmation from Q4 2025 results, specifically that ex-strike gross margins hold above 26.5% and Nurse & Allied revenue turns positive year-over-year, before adding to positions.

Thesis delta

The Goldman Sachs presentation does not alter the core investment thesis; it simply reiterates the stabilization story that forms the basis of the base-case scenario. If anything, the lack of incremental positive news relative to Q3 2025 earnings may slightly dampen enthusiasm for an early re-rating, but the thesis remains that cyclical normalization and mix shift can drive 40-60% upside over 12-24 months. No material shift is warranted; continue to monitor Q4 2025 results as the next major catalyst.